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Neurofibromatosis type 1 (NF1) is an autosomal dominant condition affecting around one in 3000 live births. The manifestations of
this condition are extremely variable, even within families, and genetic counselling is consequently difficult with regard to prognosis.
Individuals with NF1 are acknowledged to be at increased risk of malignancy. Several studies have previously attempted to quantify
this risk, but have involved relatively small study populations. We present prospective data from 448 individuals with NF1 with a total
of 5705 years of patient follow-up. These data have been collected via the UK NF1 association for patients. Demographic information
on the affected individuals was cross-referenced with UK cancer registry data by the UK Office of National Statistics. The overall risk
of cancer was 2.7 times higher in this cohort of NF1 patients than in the general population (95% confidence interval (CI) 1.9–3.7).
The cumulative risk of a malignancy by age 50 years was 20% (95% CI 14–29%); beyond this age, the risk of cancer was not
significantly elevated (P¼0.27). The most frequent types of cancer were connective tissue (14% risk by age 70, 95% CI 7.8–24%)
and brain tumours (7.9, 95% CI 3.9–16%). There was no statistically significant excess of cancers at other sites (P¼0.22).
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Neurofibromatosis type 1 (NF1) (OMIM 162200), formerly called
von Recklinghausen disease, is an autosomal dominant condition
affecting one in 3000 live births (Huson et al, 1989). Until recently,
diagnosis of this condition has only been made according to
well-established clinical diagnostic criteria (Gutmann et al, 1997).
Following the isolation of the gene responsible in 1990 (Viskochil
et al, 1990; Wallace et al, 1990), molecular diagnosis can now be
made. From the diagnostic criteria, it is clear that NF1 may
involve almost every organ system in the body, with considerable
inter-familial and intra-familial variation in manifestations of
the condition (Huson SM). Neurofibromatosis type 1 can remain
static or be rapidly progressive, but it is not currently possible to
predict outcome for individuals. For these reasons, genetic
counselling in NF1, with regard to its non-malignant manifesta-
tions, is difficult. In addition, the spectre of an increased
risk of malignancy in these individuals causes great concern for
families.
This increased cancer risk has been variously estimated by
several groups around the world, but has not been clearly
delineated. Previous data have indicated overall additional
malignancy risks in NF1 of between 5 and 15% (Sorensen et al,
1986; Huson et al, 1988; Baptiste et al, 1989; Matsui et al, 1993;
Stiller et al, 1994; Friedman and Birch, 1997; Zoller et al, 1997;
Evans et al, 2002), and these figures are commonly used when
counselling patients; therefore, a more specific risk based on a
larger study population would be useful. In addition, the advent
of surveillance techniques for early detection and subsequent
treatment of malignancy suggested that a more detailed analysis of
the question of malignancy risk in NF1 was needed.
To address this question, we now present prospective data
concerning the incidence and type of malignant tumours in a
cohort of 448 individuals with NF1.
MATERIALS AND METHODS
Families were recruited where at least one member was affected
by NF1 via the UK patient support group for this condition
(previously known as LINK, now called the Neurofibromatosis
Association UK). These families completed a demographic data
collection form detailing which family members were affected by
NF1. All the patients recruited for the study had been diagnosed
with NF1 by either a hospital doctor or a general practitioner, and
the forms submitted by the families were reviewed by the authors
to ensure that each patient had a high likelihood of a diagnosis
of NF1.
Data on these individuals were submitted to the UK Office of
National Statistics, where cross-referencing with UK cancer
registries occurred. We could thus obtain information about these
individuals with regard to mortality and cancer incidence.
Received 24 March 2006; revised 9 May 2006; accepted 17 May 2006;
published online 20 June 2006
*Correspondence: Dr D Baralle, Department of Medical Genetics, Box
134, Addenbrookes Hospital, Hills Road, Cambridge CB2 5BQ, UK.
E-mail: db314@cam.ac.uk
British Journal of Cancer (2006) 95, 233–238




















sEthical approval was obtained at the beginning of the project
Protocol No: 511, Royal Marsden Hospital.
Description of the cohort
A total of 464 individuals with a clinical diagnosis of NF1 were
initially included in the study cohort. Individuals came from 299
different families, with a median number of individuals per family
of one (189 families with one member, 68 with two, 31 with three,
nine with four and two families with five members). The cohort
contained 231 male (49.8%) and 233 female (50.2%), with dates of
birth between 1918 and 1990 (median birth year¼1965, inter-
quartile range (IQR)¼1949–1978).
Participants were followed up prospectively, starting at the date
that the patient’s ‘form’ was returned to the study coordinator,
which was between 1st July 1990 and 3rd July 1991. Only the
first malignancy in each patient was considered, excluding non-
melanoma skin cancers and benign tumours, and follow-up
continued until the earliest first malignant cancer, death, eightieth
birthday or 1st April 2004, as applicable. Thirteen patients were
excluded from the cohort because their first cancer diagnosis was
before their form being returned (cases diagnosed between 1976
and 1989), and three others were excluded because they had died
before their form was returned by their next of kin.
With these exclusions, the cohort used in the main analysis
contained 448 NF1 patients (221 male and 227 female), followed
for a median of 13.6 years (range¼2.4 months to 13.8 years; 87%
of subjects accrued at least 13 years of follow-up), with a total of
5705 person-years of follow-up. This was a predominantly young
cohort of NF1 patients, with a median age at entry of 26 years
(range¼7 months to 72 years). Forty four per cent of the cohort
was younger than 20 years of age at entry.
Of the 413 NF1 patients who did not develop a malignancy
during the follow-up period, 20 were censored at their date of
death (median age at death¼45.9 years, IQR¼35.8–62.1 years).
Three others reached their eightieth birthday before the end of the
period, and the remaining 389 patients were censored at 1st April
2004 (median age at censoring¼35.9 years, IQR¼24.5–52.9).
Statistical methods
Standardised incidence ratios (SIR) were used to compare the
cancer incidence in NF1 patients with that expected in the general
population. (Note that all SIRs presented here are ratios of
observed to expected numbers of cases, not multiplied by 100.)
Expected numbers of cancers in each individual were based on the
age, sex and calendar-period specific incidence rates given for
England and Wales in Cancer in Five Continents Volumes VII and
VIII (Parkin et al, 1997, 2002) using the PYEARS program
(Coleman et al, 1989). The rates published in Volume VIII (7) are
the most recent available and cover the period 1988–1992; these
were assumed to apply up until the end of the period of follow-up.
The 95% confidence intervals (CIs) were derived as exact
confidence limits for a Poisson mean (Breslow and Day, 1997),
and two-sided P-values were also derived from the Poisson
distribution.
The analysis was repeated excluding the five cancer cases that
were reported on death certificates, but not by the cancer registry.
Standardised incidence ratios were also estimated separately for
affected individuals who were below age 50 years and for those
aged 50 years or older (the median age at first cancer diagnosis in
the cohort was 47 years).
Cumulative risks of cancer in patients were estimated by
applying the estimated SIRs for the two age groups to the
population rates for England and Wales (1992–1997) (Parkin et al,
2002).
The SIRs presented here ignore the non-independence of cancer
incidence in relatives from the same family, which would exist if
mutations in genes other than NF1 act to modify the cancer risk in
patients, or if particular NF1 mutations confer different risks of
cancer. In the absence of pedigree information, we were not able to
address this issue. Nevertheless, the assumption of independence
is unlikely to have introduced an important bias, as the majority
of families had only one (63%) or two (24%) members in the final
cohort. Two families had more than one patient with a cancer case
included in the analysis; both had one member with a brain
tumour and one member with a malignant peripheral nerve
tumour.
RESULTS
During the period of follow-up, 36 malignant tumours were
observed in the 448 individuals in the cohort (i.e. 8.0% of the
cohort had a malignancy during the follow-up period), compared
with 13.4 expected; SIR¼2.7 (1.9–3.7), Po0.0001. These are listed
in Table 1 and Appendix A. Given the number of cancers expected,
the study had a 90% power to detect an SIR of at least 2.1 at the
conventional 5% significance level. Twenty-three of the tumours
were in female (SIR¼3.07, (1.9–4.6), Po0.0001) and 13 were in
Table 1 Observed and expected numbers of cancers, with standardised incidence ratios, for cancer sites at which at least one case was observed
Cancer site ICD code (rev 10) Observed Expected SIR 95% CI P-value
Buccal cavity and pharynx C00–14 1 0.243 4.12 0.10–23.0 0.43
Oesophagus C15 1 0.285 3.52 0.09–19.6 0.50
Colorectal C18–21 2 1.48 1.35 0.16–4.87 0.87
Gall bladder C23–24 1 0.0551 18.2 0.46–101 0.11
Lung C33–34 1 1.86 0.54 0.01–3.00 0.89
Connective tissue C47,49 11 0.0900 122 61.0–219 o0.0001
Breast (female) C50 5 2.67 1.87 0.61–4.37 0.26
Ovary C56 1 0.434 2.31 0.06–12.8 0.70
Bladder C67 1 0.653 1.53 0.04–8.54 0.96
Brain/CNS C70–72 7 0.310 22.6 9.06–46.5 o0.0001
Other sites
a 1 0.209 4.79 0.12–26.7 0.38
Unknown 4 0.700 5.71 1.55–14.6 0.01
All sites
b 36 13.4 2.69 1.88–3.72 o0.0001
All sites:
b male 13 5.89 2.21 1.17–3.78 0.015
All sites:
b female 23 7.50 3.07 1.95–4.61 o0.0001
All sites other than brain or connective tissue 18 13.0 1.38 0.82–2.18 0.22
SIR¼standardised incidence ratio, CI¼confidence interval.
aThe ‘other’ cancer was of the parathyroid gland at age 35 years.
bAll cancer sites excluding non-melanoma skin
cancer.
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smale (SIR¼2.2 (1.2–3.8), P¼0.015). The difference in the
incidence ratios between the sexes was not significant (P¼0.34).
The most commonly observed types of cancer were connective
tissue tumours (11 cases) and brain tumours (seven cases).
Together, these comprise half of the tumours reported. These types
of tumour are extremely rare in the general population; hence, the
ratios of observed/expected tumours in these two categories are
highly significant. The excess risk for both types of tumour were
evenly distributed between the sexes; there were six connective
tissue tumours in male (SIR¼128 (46.9–279), Po0.0001) and five
in female (SIR¼116 (37.6–270), Po0.0001), P¼0.88 for the
difference between the male and female SIRs. Similarly, there were
four brain tumours in male and three in female; SIR¼23.8 (6.5–
60.9) P¼0.0001 and SIR¼21.2 (4.4–61.8) P¼0.0009, respectively,
P¼0.88 for the difference. Of the brain/CNS tumours detected by
this study, astrocytomas were the most common histological type,
with cranial nerve gliomas also well represented.
Excluding connective tissue and brain/CNS tumours, the risk of
cancer was not significantly higher than expected in the general
population (SIR¼1.4 (0.8–2.2) P¼0.22). There was actually a
nonsignificant deficit in males (three cancers, SIR¼0.53 (0.1–1.5),
P¼0.37), but some evidence of an excess in females (15 cancers,
SIR¼2.0 (1.2–3.4) P¼0.017). The 15 tumours in females
comprised two colorectal cancers, four at unknown sites and five
breast cancers, along with single case each of lip, ovarian, bladder
and parathyroid cancer, none of which represented a statistically
significant increase in risk. This sex ratio replicates that of other
groups reporting malignancy in NF1 (22), but may be partly
explained by the specific types of cancer observed.
The overall cancer risk was significantly increased in patients
younger than 50 years of age; SIR¼6.5 (4.1–9.8), Po0.0001
(Table 2a). The connective tissue tumours and brain/CNS tumours
were both significantly more frequent than in the general
population (SIR¼132 (48.6–289) Po0.0001 and SIR¼47.8
(19.2–98.4) Po0.0001, respectively). The overall cancer risk
excluding these two groups of sites was also significantly elevated.
The risk of breast cancer was significantly higher in this age group
than in the general population; SIR¼4.0 (1.1–10.3), P¼0.037. Of
five cases of breast cancer diagnosed in the cohort, four were
before age 50 years (ages 39, 43, 46 and 48 years), and the fifth case
was diagnosed at age 56 years. Four out of the five breast cancers
were of ductal type, and the fifth was lobular histology.
In contrast, the overall risk of cancer was not significantly
increased beyond age 50 years (14 cases, SIR¼1.40 (0.7–2.4)
P¼0.27) (Table 2b). In this cohort, there were relatively fewer
patient-years of follow-up in this age group limiting, the power to
detect a significant effect, although the power to detect a two-fold
increase in risk was still 75% (at the 5% significance level). There
were no brain/CNS tumours beyond this age in the cohort, but
the five connective tissue tumours were significantly more than
expected in the general population.
Thirty-one of the 36 cancers included in the analysis had been
formally confirmed by Cancer Registry report; four of the five
cases reported only on death certificates were connective tissue
tumours, and the fifth was of unknown site. Excluding these five
unconfirmed cases reduced the connective tissue SIR to 77.7
(31.2–160), which was still highly significant (Po0.0001). The
overall SIR reduced slightly to 2.3 (1.6–3.3, Po0.0001) and the SIR
for ‘unknown’ cancers was no longer significant (SIR¼4.3 (0.9–
12.5, P¼0.07).
Although our analysis was restricted to first malignancies, we
noted that three of the patients went on to have a second malignant
tumour during the period of follow-up; a rectum adenocarcinoma
1 year after a lower limb malignant neurilemmoma, a peripheral
nerve malignant neurilemmoma 5 years after a tonsil carcinoma
and an upper limb soft tissue sarcoma 5 months after a thorax soft
tissue fibrosarcoma.
The cumulative risk of any malignancy in an NF1 patient by age
50 years was estimated to be 20% (95% CI 14–29%), with a 36%
risk by age 70 years (95% CI 27–46%), as compared with a risk of
Table 2 (a) Observed and expected numbers of cancers diagnosed below age 50 years, with SIR, for cancer sites at which at least one case was observed
and (b) observed and expected numbers of cancers diagnosed at age 50 years or above, with SIR, for cancer sites at which at least one case was observed
Cancer site ICD code (rev 10) Observed Expected SIR 95% CI P-value
(a)
Buccal cavity and pharynx C00–14 1 0.070 14.3 0.36–46.5 0.14
Colorectal C18–21 1 0.201 4.97 0.13–27.7 0.18
Gall bladder C23–24 1 0.0064 157 3.97–875 0.013
Connective tissue C47,49 6 0.0453 132 48.6–289 o0.0001
Breast (female) C50 4 0.994 4.02 1.09–10.3 0.037
Bladder C67 1 0.0725 13.8 0.35–76.8 0.14
Brain/CNS C70–72 7 0.147 47.8 19.2–98.4 o0.0001
Other sites
a 1 0.0669 15.0 0.38–83.3 0.13
All sites
b 22 3.38 6.51 4.08–9.82 o0.0001
All sites:
b male 7 1.13 6.22 2.49–12.8 0.0003
All sites:
b female 15 2.26 6.65 3.72–11.0 o0.0001
All sites other than brain or connective tissue 9 3.19 2.82 1.29–5.36 0.011
(b)
Oesophagus C150 1 0.252 3.97 0.10–22.1 0.45
Colorectal C18–21 1 1.28 0.781 0.02–4.35 1.00
Lung C33–34 1 1.69 0.592 0.01–3.29 0.99
Connective tissue C47,49 5 0.0447 112 36.2–261 o0.0001
Breast (female) C50 1 1.67 0.599 0.02–3.33 0.81
Ovary C56 1 0.304 3.30 0.08–18.4 0.52
Unknown 4 0.599 6.68 1.82–17.1 0.0067
All sites
b 14 10.0 1.40 0.76–2.35 0.27
All sites:
b male 6 4.76 1.26 0.46–2.75 0.69
All sites:
b female 8 5.24 1.53 0.66–3.01 0.32
All sites other than brain or connective tissue 9 9.80 0.92 0.42–1.75 0.97
SIR¼standardised incidence ratio, CI¼confidence interval.
aThe ‘other’ cancer was of the parathyroid gland at age 35 years.
bAll cancer sites excluding non-melanoma skin
cancer.
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saround 18% in the general population of England and Wales. This
includes a 14% risk of connective tissue cancers (95% CI 7.8–24%)
and a 7.9% risk of brain and central nervous system malignancies
(95% CI 3.9–16%, as compared with population risks of around
0.12 and 0.46%, respectively, by age 70 years.
Of the 448 individuals in the cohort, 197 were below the age of
20 years at the beginning of the period of follow-up, enabling us to
estimate risks of childhood cancer in NF1 patients. Six cancers
were observed in patients younger than 20 years old, giving an SIR
of 27.8 for this age group (95% CI¼10.1–60.2, Po0.0001). This is
equivalent to an absolute risk of 7.0% by age 20 years (95%
CI¼3.2–14.9%), or around 1 in 14, compared to a risk of around 1
in 380 in the general population. Four of the cancers were brain
tumours and two were connective tissue cancers (Appendix A).
DISCUSSION
This prospective study further delineates the risks of malignancy
in NF1 patients and will thus provide useful information for
clinicians who are advising families in this difficult area. The
overall risk of cancer was increased by a factor of 2.7 in these
patients, but this was largely owing to marked increases in the
risks of brain/CNS and connective tissue tumours. Excess cancer
risks were more evident below age 50 years. The data suggesting a
possible earlier onset of breast cancer in individuals with NF1 are
particularly important, given the possible screening implications.
The main strengths of this study are the large sample size (and
hence, high statistical power to detect a modest increase in cancer
risk) and the combination of a prospective design with the use of
cancer registry information to remove possible recall or reporting
biases. Patients with a diagnosis of cancer before their enrolment
in the study were excluded, avoiding the possibility that patients
who had had a cancer might be more motivated to take part.
Recruiting patients via a support group is unlikely to have biased
the results, unless NF1 patients who are members of the support
group have a different risk of cancer than the wider population of
NF1 patients.
Previous reports of malignancy rates in NF1 had varied in their
assessment of the risks associated with this condition. In the
longitudinal study by Sorensen et al (1986), 212 patients with
NF1 were followed up over a period of 40 years, and 57 malignant
tumours were found in this population. Although many of these
tumours were those seen commonly in the general population,
there was a greatly increased rate of CNS tumours in the study
group, particularly gliomas. The authors acknowledged that their
results were limited by the ascertainment method: patients were
recruited via hospital clinics and thus may well have had a greater
incidence of complications consequent to NF1. It is not clear
whether the presence of multiple manifestations of NF1 increases
the chance of malignancy for that individual, although the
presence of neurofibromas is recognised as a risk factor for
malignant peripheral nerve sheath tumours (MPNST) (Evans et al,
2002).
Another longitudinal Scandinavian study (Zoller et al, 1997)
estimated the rates of malignancy in 70 adult patients with NF1.
Around 15% of patients in this cohort developed malignant
tumours in a 12-year follow-up period, which greatly exceeds our
incidence rate for malignant tumours. Their relative risk estimate
of 4.0 (95% CI¼2.0–7.1) was also greater than our estimate of 2.7
(95% CI¼1.9–3.7), with a different range of observed tumour
types. In our larger study, we report a preponderance of brain/CNS
and connective tissue tumours, whereas although sarcomas were
reported in 7% of individuals with NF1, this Swedish study
reported no individuals with CNS malignancy. The reason for this
apparent discrepancy may be that the Swedish cohort only
included adult patients, whose mean age at the start of the study
was 44 years (range 20–81 years), in contrast to our UK cohort,
whose mean age at entry was 27 years (range¼7 months to 72
years). We observed only one CNS malignancy after 40 years of age
(a malignant neurofibrosarcoma of the spinal cord in a 49-year-old
male).
The only other UK-based study of general malignancy in NF1
patients was the cross-sectional population-based study by Huson
et al (1988). This study was, perhaps, the least likely to be biased
towards ascertainment of cancer. The data generated by this study
gave a higher CNS malignancy rate than ours, at 4.4%, with an
overall malignancy risk of 7%. Another, larger, population-based
study in the USA (Friedman and Birch, 1997) gave an overall risk
of malignancy of 4.6%, with CNS malignancy risk at 2%. Neither
study estimated relative risks for the observed number of
malignancies compared to that expected in the general population.
The other approach used to study the risk of cancer in NF1 is to
ascertain the number of cases of NF1 in a population of cancer
patients. This has been carried out previously by Matsui et al
(1993) and Baptiste et al (1989). Although both these studies
verified the increased risk of cancer in NF1, there are problems
with this type of study in terms of ascertainment bias.
The other types of study in this area reported in the literature
are those involving mortality statistics. An early Japanese study
by Imaizumi (1995) found that the average age of death from
‘neurofibromatosis’ was 43 years. One of the major problems with
this study in the context of our work is that it included patients
with both NF1 and NF2. Given the high incidence of CNS tumours
(mostly vestibular schwannomas) in NF2 patients, it is not possible
to extrapolate the data in this study to our work.
Another more recent study that of Rasmussen et al (2001) found
that overall survival in individuals with NF1 is reduced by some 15
years in comparison with that expected in the general population.
The most increased relative risk of tumours causing death in this
population involved those of connective tissue and other soft
tissue, with CNS tumours also causing significant mortality.
Other studies have reported an increased incidence of juvenile
myelomonocytic leukaemia (JMML) in children with NF1 (Stiller
et al, 1994). This malignancy has been reported to have an
association with the presence of juvenile xanthogranulomas in this
population. We did not encounter any cases of JMML in our study,
but as this is an extremely rare form of leukaemia, representing
only 1.6% of haematological malignancy in children (Arico et al,
1997), this may be owing to insufficient numbers of cases
recruited.
Other tumours have been reported as having increased
incidence in NF1. These include rhabdomyosarcoma and phaeo-
chromocytoma (Modlin et al, 1979; Hartley et al, 1988). We
encountered one case of rhabdomyosarcoma and one case of
paraganglioma. It is difficult to verify the previously reported
associations given these small numbers, as these tumours may
simply have occurred by chance.
Although we excluded neurofibromas from our figures on
overall malignancy risks, these lesions are known to be significant
precursors in the development of MPNST or neurofibrosarcomas.
More than a third of patients in our study had a reported
neurofibroma, and other cases may have existed that were not
formally registered, and therefore not reported to the study. Data
have previously been presented concerning the risks of MPNST in
NF1 (Evans et al, 2002), and a lifetime risk of 8–13% in this
population has been quoted. This corresponds to the overall 14%
(95% CI¼7.8–24%) risk of connective tissue tumours by age 70
years estimated in our cohort (the majority of which were
neurofibrosarcomas).
Finally, our study shows that the risk of breast cancer was
significantly higher in women younger than 50 years of age than in
the general population; SIR¼4.0 (1.1–10.3), P¼0.037. Of five
cases of breast cancer diagnosed in the cohort, four were before
age 50 years, and the fifth case was diagnosed at age 56 years.
Although these are small numbers, if further work in this area
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sconfirms an increased risk of relatively early-onset breast cancer in
patients with NF1, this could have implications for breast
screening in this population.
This prospective study of malignancy risk in 448 patients with
NF1 has shown substantially increased relative risks for CNS and
connective tissue tumours over the general population, contribut-
ing to an estimated overall risk of malignancy of 36% (95%
CI¼27–46%) by age 70 years. This information will be useful in
counselling patients in this difficult area, but further work will be
required to delineate whether there are subgroups of patients who
can be defined molecularly as being at substantially increased risk
of malignancy, and whether screening for certain tumours, in
particular young onset breast cancer, is warranted in this group of
patients.
ACKNOWLEDGEMENTS
We thank the patients and families who participated in this study.
We also thank the NF Association UK for their assistance with data
collection and funding support. DT and DE are supported by
Cancer Research UK.
REFERENCES
Arico M, Biondi A, Pui CH (1997) Juvenile myelomonocytic leukaemia.
Blood 90(2): 479–488
Baptiste M, Nasca P, Metzger B, Field N, Macgubbin P, Greenwald P,
Armbrustmacher V, Waldman J, Carlton K (1989) Neurofibromatosis
and other disorders among children with CNS tumours and their
families. Neurology 39(4): 487–492
Breslow NE, Day NE (1997) Statistical Methods in Cancer Research. The
design and analysis of cohort studies. vol. II Lyon: IARC
Coleman MP, Hermon C, Douglas A (1989) Person-years (PYRS) – a fortran
program for cohort study analysis. IARC internal report, Lyon 89/006
Evans DGR, Baser ME, McGaughran J, Sharif S, Howard E, Moran A (2002)
Malignant peripheral nerve sheath tumours in neurofibromatosis 1.
J Med Genet 39: 311–314
Friedman JM, Birch PH (1997) Type 1 neurofibromatosis: a descriptive
analysis of the disorder in 1728 patients. Am J Med Genet 70:
138–143
Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE,
Rubenstein A, Viskochil D (1997) The diagnostic evaluation and
multidisciplinary management of neurofibromatosis 1 and neurofibro-
matosis 2. JAMA 278: 51–57
Hartley AL, Birch JM, Marsden HB, Harris M, Blair V (1988) Neurofi-
bromatosis in children with soft tissue sarcoma. Pediatr Haematol Oncol
5: 7–16
Huson SM, Compston DAS, Harper PS (1989) A genetic study of von
Recklinghausen Neurofibromatosis in South East Wales. J Med Genet 26:
712–721
Huson SM, Harper PS, Compston DAS (1988) Von Recklinghausen
neurofibromatosis: a clinical and population study in South-East Wales.
Brain 111: 1355–1381
Imaizumi Y (1995) Mortality of neurofibromatosis in Japan 1968–1992.
J Dermatol 22(3): 191–195
Matsui I, Tanimura M, Kobayashi N, Sawada T, Nagahara N, Akatsuka J
(1993) Neurofibromatosis type 1 and childhood cancer. Cancer 72(9):
2746–2754
Modlin IM, Farndon JR, Shepherd A, Johnston ID, Kennedy TL,
Montgomery DA, Welbourn RB (1979) Phaeochromocytoma in 72
patients: clinical and diagnostic features, treatment and long-term
results. Br J Surg 66: 456–465
Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (1997) Cancer
Incidence in Five Continents, Vol. VII, Lyon: IARC
Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (2002) Cancer
Incidence in Five Continents, Vol. VIII, Lyon: IARC
Rasmussen SA, Yang Q, Friedman JM (2001) Mortality in neurofibroma-
tosis 1: an analysis using US death certificates. Am J Hum Genet 68:
1110–1118
Sorensen SA, Mulvihill JJ, Nielsen A (1986) Long-term follow-up of von
Recklinghausen neurofibromatosis: survival and malignant neoplasms. N
Engl J Med 314: 1010–1015
Stiller CA, Chessels JM, Fitchett M (1994) Neurofibromatosis and childhood
leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer
70(5): 969–972
Viskochil D, Buchberg AM, Xu G, Stevens J, Wolff RK, Culver M, Carey J,
Copland NG, Jenkins NA, White R, O’Connell P (1990) Deletions and
translocations interrupt a cloned gene at the neurofibromatosis type 1
locus. Cell 62: 187–192
Wallace MR, Marchuk DA, Anderson LB, Letcher R, Oden HM, Saulino
AM, Fountain JW, Brereton A, Nicholson J, Mitchell AL, Brownstein BH,
Collins FS (1990) Type 1 neurofibromatosis gene: identification of a large
transcript disrupted in three NF1 patients. Science 249: 181–186
Zoller MET, Rembeck B, Oden A, Samuelsson M, Angervall L (1997)
Malignant and benign tumours in patients with neurofibromatosis type 1
in a defined Swedish population. Cancer 79: 2125–2131
UK Cancer incidence in NF1
L Walker et al
237




















List of the 36 cancers used in this analysis (Table A1)
Table A1
ICD code (rev 10) Age at diagnosis Sex Description of tumour
C09.9 47 F Tonsil squamous cell carcinoma
C15.9 72 M Oesophagus adenocarcinoma
C18.4 53 F Transverse colon adenocarcinoma
C20.0 40 F Adenocarcinoma of rectum
C24.1 37 M Carcinoma of Ampulla of Vater
C34.2 75 M Squamous cell carcinoma of lung
C47.2 25 F Lower limb neurofibrosarcoma
C47.1 69 M Lower limb malignant neurilemmoma/schwannoma
C47.3 47 F Thoracic peripheral nerve neurofibrosarcoma
C47.3 53 F Malignant tumour of peripheral nerves (thorax)
a
C47.3 47 M Spindle cell sarcoma of thoracic peripheral nerve
C47.9 55 M Small bowel neurofibrosarcoma
C47.9 50 M Malignant peripheral nerve tumour
a
C47.9 14 F Neurofibrosarcoma
a
C49.1 70 M Upper limb myxoid chondrosarcoma
C49.3 19 F Thorax soft tissue fibrosarcoma
C49.9 22 M Fibrosarcoma
a
C50.9 48 F Breast infiltrating duct carcinoma
C50.9 56 F Breast ductal carcinoma
C50.9 39 F Breast ductal carcinoma
C50.9 46 F Lobular breast carcinoma
C50.9 43 F Ductal breast carcinoma
C56.0 55 F Ovarian carcinoma
C67.9 49 F Bladder transitional cell carcinoma
C71.9 39 F Brain (unspecified) astrocytoma
C71.9 17 M Brain malignant neoplasm
C71.9 4 F Brain (unspecified) astrocytoma
C72.0 49 M Malignant neurofibrosarcoma of spinal cord
C72.5 30 M CNS neurofibrosarcoma
C72.5 8 M Cranial nerve malignant glioma
C72.9 7 F CNS glioma
C74.1 35 F Adrenal gland malignant neoplasm
C80.0 62 F Metastatic adenocarcinoma (unspecified site)
C80.0 64 F Metastatic adenocarcinoma (unspecified primary)
a
C80.0 73 F Metastatic adenocarcinoma (unspecified primary)
C80.0 51 F Carcinomatosis (unspecified primary)
aCancer report obtained from death certificate, not reported by Cancer Registry.
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